Other Health

Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Retrieved on: 
Tuesday, June 20, 2023
Science, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Other Health, Hodgkin lymphoma, Doxorubicin, Inc., Vincristine, Brentuximab vedotin, Vinblastine, PML, Takeda, Progression-free survival, Hematology, ABVD, ICML, Procarbazine, Survival, Lymphoma, PET, Cyclophosphamide, Bleomycin, ADCETRIS, CHL, PFS, Teaching hospital, Dexamethasone, FSH, Research and development, Dacarbazine, Prednisone, Development, Etoposide, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Risk, Progressive multifocal leukoencephalopathy, Fertility, BEACOPP, Peripheral neuropathy, Death, Society, Conference, Pharmaceutical industry, Birth control, Seagen

The data results of the HD21 study were presented in a late-breaking session at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on June 17.

Key Points: 
  • The data results of the HD21 study were presented in a late-breaking session at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on June 17.
  • 12-month post-treatment safety data were consistent with previously presented HD21 data results at the American Society of Hematology 2022 Annual Meeting.
  • Preservation of fertility potential was indicated by measurement of follicle-stimulating hormone (FSH) and was available for 597 patients.
  • Please see Important Safety Information, including a BOXED WARNING for progressive multifocal leukoencephalopathy (PML), for ADCETRIS below.

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

Retrieved on: 
Tuesday, June 20, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Physiology, Rat, MMF, Hypercalciuria, Magnesium, European Renal Association, CSA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Lupus, Kidney, Calcium, Nephritis, ERA, Proteinuria, TAC, Patient, VCS, Annual general meeting, CNI, UPCR, Safety, Pharmaceutical industry, LN, Aurinia

The findings presented at ERA this week show that voclosporin achieved a 50% proteinuria reduction at 28 days, compared to 57 days in the control arm (p90% renal reabsorption was observed for both CSA and TAC in this study, whereas the renal handling of VCS suggested a significant component of tubular secretion.

Key Points: 
  • The findings presented at ERA this week show that voclosporin achieved a 50% proteinuria reduction at 28 days, compared to 57 days in the control arm (p
  • “Additionally, in two pre-clinical animal models, voclosporin showed a higher rate of renal secretion, lower overall kidney exposure, and no associated hypercalciuria or hypomagnesemia, compared to the legacy, first-generation CNIs.
  • Higher drug exposure and >90% renal reabsorption was observed for both CSA and TAC in this study, whereas the renal handling of VCS suggested a significant component of tubular secretion.
  • The data showed that the tubulotoxicity observed with TAC is not apparent with VCS treatment at clinically relevant doses.3

Swiss Health Science Company Amazentis Announces New CEO and Rebranding

Retrieved on: 
Tuesday, June 20, 2023
Research, Fitness & Nutrition, Other Health, Biotechnology, Food, Beverage, General Health, Health, Retail, Science, Other Science, Carbon, Whole Foods Market, Garden State Life Insurance Company, Ageing, Amazon (company), Longevity, Timeline, Management, Life, Target

Amazentis, an innovative Swiss health science company at the forefront of longevity research, today announced the appointment of a new Chief Executive Officer, Brian Ray.

Key Points: 
  • Amazentis, an innovative Swiss health science company at the forefront of longevity research, today announced the appointment of a new Chief Executive Officer, Brian Ray.
  • Brian was most recently the Chief Executive Officer of Garden of Life, a company which he co-founded in 2000 and later sold to Nestlé Health Science.
  • Chris Rinsch, co-founder of Amazentis and its founding CEO will take on the role of President and will assume the responsibility for international markets, global innovation and skin health.
  • Along with this addition to the leadership team, the company also revealed that it will be rebranding, changing its brand name from Amazentis to Timeline®.

Northwest Pain Care Selects eClinicalWorks Cloud EHR to Enable Faster Data-Driven Decisions at the Point of Care

Retrieved on: 
Tuesday, June 20, 2023
Technology, Health Technology, Software, Practice Management, Other Health, Managed Care, General Health, Health, Data Management, Oncology, Insurance, Multimedia, Abbreviation, Providence Sacred Heart Medical Center and Children's Hospital, Cancer pain, Hospital, Aggregate, EHR, Medical Center, PRISMA, Behavioral medicine, Nursing

eClinicalWorks® , the largest ambulatory cloud EHR, today announced that Northwest Pain Care recently selected eClinicalWorks to help the practice provide comprehensive care, improve efficiency, and lower patient wait times with the industry’s first health information search tool, PRISMA .

Key Points: 
  • eClinicalWorks® , the largest ambulatory cloud EHR, today announced that Northwest Pain Care recently selected eClinicalWorks to help the practice provide comprehensive care, improve efficiency, and lower patient wait times with the industry’s first health information search tool, PRISMA .
  • The one patient, one record approach collates medical information from specialties, urgent care facilities, hospitals, and primary care providers to enable faster and more accurate decision-making.
  • View the full release here: https://www.businesswire.com/news/home/20230620201137/en/
    PRISMA will aid Northwest Pain Care in its mission to provide exceptional and effective management of acute, chronic, and cancer pain.
  • “With PRISMA, we can now access patient data at the point of care,” said Hilary Severn, practice manager of Northwest Pain Care.

Pearl Bio Secures Breakthrough IP for Multi-Functionalized Biologics

Retrieved on: 
Tuesday, June 20, 2023
Biotechnology, FDA, Diabetes, Health, Legal, Other Health, Pharmaceutical, Professional Services, Oncology, Other Science, Research, Infectious Diseases, Genetics, Science, Yale University, Quality of life, Coronavirus Scientific Advisory Board, Protein, DRS, Bio, Cell, Toxicity, Patent, Tumor microenvironment, Synthetic biology, Khosla Ventures, Stanford University, Engineering, Pharmaceutical industry

Pearl Bio , a synthetic biology company backed by Khosla Ventures, is recoding life to create a new era of biologics and biomaterials.

Key Points: 
  • Pearl Bio , a synthetic biology company backed by Khosla Ventures, is recoding life to create a new era of biologics and biomaterials.
  • A newly issued breakthrough U.S. patent 11,649,446 related to engineering programmable biologics by encoding synthetic chemistries bolsters Pearl’s patent portfolio to corner the market of multi-functionalized biologics with Pearl’s exclusive license to the issued patent.
  • The Pearl team includes world leaders in synthetic biology, genome recoding, and ribosome engineering: Drs.
  • George Church (Pearl Bio, Scientific Advisory Board), Farren Isaacs (Yale University), Michael Jewett (Stanford University) and Jesse Rinehart (Yale University).

Dompé Foundation Doubles Its Funding for Rita Levi Montalcini fellowships in Neuroscience and Neurobiology

Retrieved on: 
Tuesday, June 20, 2023
Mental Health, Health, Other Health, Other Science, Research, Science, Biotechnology, Call, Bocconi University, Ambassador, University of Pittsburgh, University, Digital Public Library of America, Education, Stanford University, Public, Multimedia, Washington University in St. Louis, Female, Queen Mary University of London, Georgetown University, Doctor of Philosophy, Harvard Medical School, Student, Johns Hopkins University, Investment, MA, STEM, Sarnoff Fellowship, Weill Cornell Medicine, Memory, University of Chicago, Pharmaceutical industry, Management, Nursing, Neuroscience, Yale University, Medicine

The Dompé Foundation has announced it doubled to 1 million dollars its support to MA, PhD and post-doc candidates from United States-based universities for 2023.

Key Points: 
  • The Dompé Foundation has announced it doubled to 1 million dollars its support to MA, PhD and post-doc candidates from United States-based universities for 2023.
  • As with former grants, the Foundation will offer scholarships and fellowships to the most promising candidates.
  • "Investment in young researchers is a guarantee of success in terms of scientific discoveries and economic progress," Ambassador Zappia pointed out in expressing appreciation for the opportunities provided by the Dompé Foundation.
  • The Foundation’s commitment to the progress of scientific knowledge is part of Dompé farmaceutici’s long lasting investments in R&D and innovative startups.

Rhinostics and FutureMed Bring Innovative Dry Transport Technologies for Clinical Labs to Chile, developed amid the COVID-19 Pandemic

Retrieved on: 
Tuesday, June 20, 2023
Health, Other Health, Pharmaceutical, Other Science, Practice Management, Research, Infectious Diseases, General Health, Hospitals, Genetics, Science, COVID-19, Clinical Trials, Medical Supplies, DNA, Biochemistry, Coronavirus, VTM, Harvard Medical School, Patient, Laboratory, Collection, Wyss Institute, Hematology, Vertically transmitted infection, FDA, Wyss Institute for Biologically Inspired Engineering, Pharmaceutical industry, Fine chemical, Vaccine, FutureM

The optimization of their operational capabilities and the incorporation of new technologies to overcome technical limitations in the pre-analytical and analytical stages, should be considered a permanent priority in health strategies.

Key Points: 
  • The optimization of their operational capabilities and the incorporation of new technologies to overcome technical limitations in the pre-analytical and analytical stages, should be considered a permanent priority in health strategies.
  • To this end, FutureMed, an advanced medical solutions company, is partnering with Rhinostics to bring Dry Transport Technologies to clinical laboratories in Chile.
  • "Several of the traditional limitations of clinical labs have now been resolved by these innovative products," explains Mateo Ibarcena, CEO of FutureMed and the exclusive representatives of Rhinostics for Chile.
  • Rhinostics' suite of sample collection devices is registered with the FDA as Class 1 medical devices.

Eptura Bolsters Building Occupant Safety with Dynamic Emergency Notifications to Support New Flexible Working Styles

Retrieved on: 
Tuesday, June 20, 2023
Other Health, General Health, Mobile, Wireless, Networks, Internet, Data Management, Apps, Applications, Technology, Medical Devices, Hospitals, Biotechnology, Health, Telecommunications, Workplace, Michigan Occupational Safety and Health Administration, Organization, OSHA, Occupational safety and health, Fire, Flood, Safety, Emergency, Risk management, Online shopping, Nursing, Management

Eptura , the global worktech leader, today announced an enhancement to its visitor management software with the new Emergency List feature to improve occupant safety and streamline the building evacuation process during emergency situations.

Key Points: 
  • Eptura , the global worktech leader, today announced an enhancement to its visitor management software with the new Emergency List feature to improve occupant safety and streamline the building evacuation process during emergency situations.
  • Events such as fires, floods, natural disasters, and more, require robust emergency preparedness strategies to account for all building occupants in the case of an evacuation.
  • In some territories, authorities mandate that businesses develop such action plans to increase the efficiency of emergency response, including the Occupational Safety and Health Administration (OSHA) regulations in the United States.
  • Key capabilities available in the Emergency List feature include:
    Send an emergency alert to people in the workplace during evacuations or drills.

Axena Health delivers at-home treatment for chronic fecal incontinence in women

Retrieved on: 
Tuesday, June 20, 2023
Biotechnology, Medical Devices, Other Health, Health, Health Technology, Depression, Femtech, UI, European Journal of Obstetrics & Gynecology and Reproductive Biology, PFMT, The Green Journal, RCT, Quality of life, Incontinence, Woman, Guilt, Research, FACOG, Medicine, Leva, Associate, Reproductive biology, Harvard Medical School, Fecal incontinence, Feces, Shame, MD, Patient, Social stigma, Social isolation, Frustration, ABL, Chairperson, FACS, FDA, Massachusetts General Hospital, Pelvic floor dysfunction, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Female, Urinary incontinence, Birth control, Pharmaceutical industry, Obstetrics, Gynaecology

Axena Health, Inc. (Axena Health), a FemTech medical device company focused on scalable treatments for female pelvic health, introduced today the Leva®Pelvic Health System for the first-line treatment of chronic fecal incontinence (FI), also called accidental bowel leakage (ABL), in women.

Key Points: 
  • Axena Health, Inc. (Axena Health), a FemTech medical device company focused on scalable treatments for female pelvic health, introduced today the Leva®Pelvic Health System for the first-line treatment of chronic fecal incontinence (FI), also called accidental bowel leakage (ABL), in women.
  • In our study, we showed that the Leva System had the potential to improve fecal incontinence symptoms, which gives both clinicians and women an easy, practical way to access first-line treatment.
  • “Pelvic floor muscle training is a first-line treatment for both urinary and fecal incontinence,” said Samantha Pulliam, MD, FACOG, chief medical officer for Axena Health.
  • Thousands have used it to relieve symptoms of urinary incontinence, and we aspire to saying the same for women who experience fecal incontinence.

Adtalem Global Education Unveils Growth with Purpose Strategy to Drive Sustainable Growth

Retrieved on: 
Tuesday, June 20, 2023
Nursing, Finance, Professional Services, Other Health, Other Education, Health, University, General Health, Education, Growth, Adtalem Global Education, Health care, Chamberlain University, Knowledge, CDT, Partnership, ATGE, Investment, NYSE, Marketing, Management

Adtalem Global Education Inc. (NYSE: ATGE), a national leader in post-secondary education and a leading provider of professional talent to the healthcare industry, will today host an Investor Day at its Chamberlain University Chicago campus, beginning at 9:00 a.m. CDT.

Key Points: 
  • Adtalem Global Education Inc. (NYSE: ATGE), a national leader in post-secondary education and a leading provider of professional talent to the healthcare industry, will today host an Investor Day at its Chamberlain University Chicago campus, beginning at 9:00 a.m. CDT.
  • At the event, members of the executive leadership team will unveil Adtalem’s long-term growth strategy and elaborate on the path to achieve its financial targets through fiscal year 2026.
  • “Adtalem’s mission is to provide access to knowledge, transforming lives and enabling careers while achieving positive academic and societal outcomes,” shared Steve Beard, Adtalem Global Education president and chief executive officer.
  • The Adtalem leadership team reaffirms its fiscal year 2023 guidance and will discuss its updated financial targets that align with the company’s strategic initiatives, and commitment to drive shareholder value, including: